{
  "id": 928158,
  "title": "Oruka Therapeutics GC Paul Quinlan sells $5.64m stock",
  "url": "https://urgent.news/2026/08/15/oruka-therapeutics-gc-paul-quinlan-sells-5-64m-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-15T01:31:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/oruka-therapeutics-gc-paul-quinlan-sells-564m-stock-93CH-4861676"
  },
  "original_language": "en",
  "account": "In a notable transaction on August 14, 2026, Paul T. Quinlan, General Counsel at Oruka Therapeutics, sold 52,000 shares of the company's common stock, generating approximately $5.64 million in proceeds. The shares were sold at a range of $106.0504 to $111.1378 per share. The current stock price of $111.04 is just 1% below its 52-week high of $111.37, following an impressive 622% return over the past year. UBS raised its price target for Oruka Therapeutics to $130, while H.C. Wainwright maintained a Buy rating with a $120 target. Piper Sandler affirmed an Overweight rating with a $180 price target. Despite the company's positive financial news, InvestingPro analysis suggests that Oruka Therapeutics is currently overvalued.",
  "summary": null,
  "key_points": [
    "Paul T. Quinlan sold 52,000 shares of Oruka Therapeutics stock",
    "Transaction generated $5.64 million in proceeds",
    "Stock price at $111.04 is near 52-week high"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}